Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Katharina Gunzer"'
Autor:
François Gernier, Jean-Michel Grellard, Charlotte Dupont, Hervé Castel, Marie Fernette, François Lahaye, Rose-Marie Charles, Tiphaine Leroux, Céline Ory, Audrey Faveyrial, Adeline Morel, George Emile, Christelle Levy, Carine Segura, Djelila Allouache, Alison Johnson, Julien Geffrelot, Katharina Gunzer, Anaïs Lelaidier, Gilles Girault, Coraline Dubot-poitelon, Chankannira San, Justine Lequesne, Bénédicte Clarisse
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Non-metastatic breast cancer treatment is mainly based on surgery, with or without chemotherapy, radiotherapy and/or hormone therapy. To reduce the risk of hormone receptor positive (HR+) disease recurrence, hormone therapy is pre
Externí odkaz:
https://doaj.org/article/26a7a9b19d2643669b2a86b963b0dcee
Autor:
Angélique Da Silva, George Emile, C. Segura, Audrey Faveyrial, Idlir Licaj, Christelle Levy, Ioana Hrab, Adeline Morel, Gandhi Damaj, Alison Johnson, D. Allouache, Katharina Gunzer
Publikováno v:
Anticancer Research. 40:2955-2960
Background/aim Currently, there is no recommendation for the treatment of breast cancer (BC) with bone-marrow cell infiltration (BMI). We evaluated the efficacy and safety of weekly-paclitaxel in this population. Patients and methods This retrospecti
Autor:
Katharina Gunzer, Russell D. Petty, Bernardo Miguel-Lillo, Gianluca Laus, Jorge Luis Iglesias Dios, Maria Alsina, Alan Anthoney, Clara Montagut, Jean-Philippe Metges, Anthony Gonçalves, Patrick Bohan, Jennifer Brown, Ramon Salazar
Publikováno v:
Cancer Chemotherapy and Pharmacology. 77:819-827
To determine the recommended dose and antitumor activity of single-agent elisidepsin as a 24-h intravenous (i.v.) infusion fortnightly [biweekly, d1 and 15 every 4 weeks (q4wk); Arm A, dose-intensity strategy] or as a 3-h i.v. infusion weekly (d1, 8,
Autor:
Florence Joly, C. Delcambre, Audrey Faveyrial, Elodie Coquan, Sophie Gouérant, M.P. Galais, Katharina Gunzer, Laure Kaluzinski, Emmanuel Sevin, Florence Polycarpe, Gilles Saucier, Julie Vanbockstael, Ioana Hrab, Radj Gervais, A.-C. Lefebvre, Michel André, Bénédicte Clarisse, Jean-Michel Grellard, J.F. Héron, D. Allouache, Sabine Noal, Brigitte Vie, Noëmie Lemenand, Audrey Emmanuelle Dugué
Publikováno v:
Supportive Care in Cancer. 24:1131-1138
Chemotherapy-induced nausea and vomiting (CINV) still remain frequent. The procedure for announcing the diagnosis (PAD) was an emblematic measure of the first French Plan Cancer aiming at providing patients with time to listen, information after canc
Autor:
Sara Grossi, Gérard Zalcman, Karine Bouhier-Leporrier, Dominique Maron, Corinne Delcambre-Lair, Brice Dubois, Minh-Dung Ngo, Katharina Gunzer, Bénédicte Clarisse, Vincent Launay-Vacher, Laure Kaluzinski, Stephanie Lheureux, Florence Joly
Publikováno v:
Anti-Cancer Drugs. 22:919-925
Adverse effects induced by cytotoxic chemotherapy (CT) have been mostly evaluated in clinical trials. The aim of this study was to assess in a nonselected patients group the incidence of CT-related toxicities and to identify risk factors in daily pra
Autor:
Steven Le Gouill, Gilles Salles, Fabrice Jardin, Jehan Dupuis, Lionel Karlin, Christophe Bonnet, Christophe Fruchart, Roch Houot, Katharina Gunzer, Thierry Lamy, Thomas Gastinne, Hervé Tilly
Publikováno v:
Journal of Clinical Oncology. 36:e19550-e19550
e19550Background: Ibrutinib (Ibru) has shown therapeutic activity in patients (pts) with various B-cells malignancies, making it an appropriate drug to combine with R-DHAP/Ox chemotherapy in pts wi...
Autor:
Fabrice Jardin, Hervé Tilly, Gilles Salles, Thierry Lamy, Katharina Gunzer, Jehan Dupuis, Thomas Gastinne, Christophe Bonnet, Christophe Fruchart, Roch Houot, Steven Le Gouill, Lionel Karlin
Publikováno v:
Hematological Oncology. 35:410-410
Background: Ibrutinib is a first-in-class selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK) approved for the treatment of patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) and R/R chronic lymphocytic leukemia. In
Publikováno v:
Expert opinion on biological therapy. 10(4)
Granulocyte colony-stimulating factors (G-CSFs) such as lenograstim have improved the management of cancer patient treatments for 15 years. Their use in preventing chemotherapy-induced febrile neutropenia and for progenitor-cell transplantation has b
Autor:
D. Allouache, Iona Hrab, Joelle Lacroix, Youlia M. Kirova, François Campana, Louis Gras, Marie-Pierre Sunyach, Audrey Emmanuelle Dugué, Bénédicte Clarisse, Julien Geffrelot, Jean-Marc Constans, Jean-Michel Grellard, Marc-André Mahé, C. Hanzen, Emilie Le Rhun, Christelle Levy, Xavier Paoletti, Katharina Gunzer, Stéphane Supiot, Marianne Leheurteur
Publikováno v:
Journal of Clinical Oncology. 32:2054-2054
2054 Background: BM, the most frequent malignancy in the central nervous system, remains of poor prognosis. Standard treatment is WBRT. Neo-angiogenesis plays an important role in BM growth. Angiog...
Autor:
Martina Uttenreuther-Fischer, H. de Mont-Serrat, Jean-Louis Misset, Katharina Gunzer, trial team
Publikováno v:
Journal of Clinical Oncology. 28:1072-1072
1072 Background: Inhibition of HER1/2 signaling via possible cross-talk between the ER and HER1/2 signaling pathways restores hormone sensitivity in animal models and may show clinical efficacy. BIBW 2992 is an oral, irreversible inhibitor of the EGF